Boston Scientific Corporation (NYSE: BSX) reported fourth-quarter results that exceeded revenue and earnings expectations, but weakness in its electrophysiology business weighed on investor sentiment, sending shares down more than 9% in premarket trading.
The medical device maker reported fourth-quarter revenue of $5.29 billion, modestly above both Stifel’s estimate of $5.25 billion and the consensus forecast of $5.28 billion. Organic revenue growth for the quarter reached 15.9%.
The company’s electrophysiology segment, which accounted for roughly 17% of total quarterly revenue, underperformed expectations. Segment revenue totaled $890 million, well below the consensus estimate of $933 million, with the shortfall primarily driven by softer demand in the U.S. market.
Boston Scientific posted earnings per share of $0.80, exceeding both Stifel’s estimate of $0.77 and the consensus forecast of $0.78. The earnings beat was largely attributed to a lower-than-expected effective tax rate of approximately 9.3%.
For 2026, the company guided for organic revenue growth of 10% to 11% and earnings per share of $3.43 to $3.49. First-quarter organic revenue growth is expected to range from 8.5% to 10%, implying stronger growth in the back half of the year.
